ISA 201

Drug Profile

ISA 201

Alternative Names: Hespecta; HPV E-Six Peptide Conjugated To AMPLIVANT®; HPV16 E6 Peptide Conjugated To AMPLIVANT®; HPV16 peptides AMPLIVANT® vaccine; ISA201; SLP AMPLIVANT® head and neck cancer vaccine

Latest Information Update: 04 Mar 2015

Price : $50

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Head and neck cancer; Human papillomavirus infections

Most Recent Events

  • 26 Feb 2015 Phase-I/II clinical trials in Human papillomavirus infections and Head and neck cancer in Netherlands (SC)
  • 14 May 2014 Preclinical trials in Human papillomavirus infections and Cancer in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top